Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: Continuous platelet inhibition by the combination of abciximab and ticlopidine

Circulation

Volumn 102, Issue 13, 2000, Pages 1490-1496

  Peter, Karlheinz ^a   Kohler, Benedikt ^a   Straub, Andreas ^b   Ruef, Johannes ^b   Moser, Martin ^b   Nordt, Thomas ^a   Olschewski, Manfred ^a   Ohman, Magnus E ^c   Kübler, Wolfgang ^b   Bode, Christoph ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Inhibitors; Platelets; Thrombolysis

Indexed keywords

ABCIXIMAB; FIBRINOGEN; FIBRINOGEN RECEPTOR; PADGEM PROTEIN; RETEPLASE; TICLOPIDINE;

ACUTE HEART INFARCTION; ARTICLE; BLOOD CLOT LYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BINDING; FIBRINOLYSIS; FLOW CYTOMETRY; HUMAN; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

EID: 0034718512     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.13.1490     Document Type: Article

References (26)

1. Toward a new frontier in myocardial reperfusion therapy: Emerging platelet prominence
2. 2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis
3. 2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis
4. Conner Memorial Lecture: Mechanisms leading to myocardial infarction: Insights from studies of vascular biology
5. Platelet GP IIb/IIIa antagonists: The first anti-integrin receptor therapeutics
6. Platelet GPIIb-IIIa blockers
7. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation
8. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp - Containing peptide bitistatin in a canine model of coronary thrombosis
9. 2 prevents rethrombosis after recombinant tissue-type plasminogen activator - Induced coronary artery thrombolysis in a canine model
10. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: Results of a randomized, placebo-controlled, dose-ranging trial
11. Enhanced early reperfusion at 60 minutes with low-dose reteplase combined with full-dose abciximab in acute myocardial infarction: Preliminary results from the GUSTO-4 pilot (SPEED) dose-ranging trial
12. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial: The TIMI 14 Investigators
13. 3) inhibitors
14. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia
15. Monitoring platelet GP IIb/IIIa antagonist therapy
16. Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa
17. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
18. Abciximab (c7E3 Fab): A review of its pharmacology and therapeutic potential in ischemic heart disease
19. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy
20. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
21. Evaluation of platelet membrane glycoproteins in coronary artery disease: Consequences for diagnosis and therapy
22. Platelet glycoprotein IIb/IIIa antagonists: What are the relevant issues concerning their pharmacology and clinical use?
23. Pharmacodynamic study of F(ab)2-Fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris
24. Ticlopidine and clopidogrel
25. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment: GUSTO-III Investigators: Global Use of Strategies to Open Occluded Coronary Arteries
26. Rapid platelet-function assay: An automated and quantitative cartridge-based method